Trial intelligence / Profile preview

LYG-LIV0001 in End-Stage Liver Disease

NCT04496479Phase 2Recruiting

Sponsor
LyGenesis
Start
Mar 2022
Primary completion
Aug 2027
Modality
Cell Therapies
Countries
1
01

Overview

A Phase 2 trial of LYG-LIV-001 in liver disease, sponsored by LyGenesis. Started Mar 2022; status: recruiting.

02

Drugs

LYG-LIV-001
03

Conditions

liver disease

Beyond the preview

Go deeper on NCT04496479.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT04496479.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call